BR112015022967A8 - anticorpos anti-gd2 de alta afinidade. - Google Patents
anticorpos anti-gd2 de alta afinidade.Info
- Publication number
- BR112015022967A8 BR112015022967A8 BR112015022967A BR112015022967A BR112015022967A8 BR 112015022967 A8 BR112015022967 A8 BR 112015022967A8 BR 112015022967 A BR112015022967 A BR 112015022967A BR 112015022967 A BR112015022967 A BR 112015022967A BR 112015022967 A8 BR112015022967 A8 BR 112015022967A8
- Authority
- BR
- Brazil
- Prior art keywords
- high affinity
- affinity anti
- antibodies
- prevention
- detection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
abstract in this application are described high affinity anti-gd2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of gd2-related diseases, in particular, neuroblastoma. tradução do resumo resumo "anticorpos anti-gd2 de alta afinidade". tratam-se de agentes de anticorpos anti-gd2 de elevada afinidade e vários métodos e reagentes relacionados com o mesmo, incluindo, por exemplo, para detecção, ´prevenção e/ou tratamento terapêutico de doenças relacionadas com gd2, em particular, neuroblastoma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801287P | 2013-03-15 | 2013-03-15 | |
US61/801,287 | 2013-03-15 | ||
PCT/US2014/029308 WO2014144763A2 (en) | 2013-03-15 | 2014-03-14 | High affinity anti-gd2 antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015022967A2 BR112015022967A2 (pt) | 2017-11-14 |
BR112015022967A8 true BR112015022967A8 (pt) | 2018-01-23 |
BR112015022967B1 BR112015022967B1 (pt) | 2023-08-29 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
EP2968545B1 (en) | 2019-03-06 |
AU2014228772A1 (en) | 2015-09-10 |
JP6482525B2 (ja) | 2019-03-13 |
CA2903576C (en) | 2021-06-08 |
US10167341B2 (en) | 2019-01-01 |
WO2014144763A2 (en) | 2014-09-18 |
AU2014228772B2 (en) | 2019-02-28 |
RU2015143208A (ru) | 2017-04-27 |
JP2016515519A (ja) | 2016-05-30 |
CA2903576A1 (en) | 2014-09-18 |
HK1216144A1 (zh) | 2016-10-21 |
CN105705165B (zh) | 2020-04-24 |
EP2968545A2 (en) | 2016-01-20 |
BR112015022967A2 (pt) | 2017-11-14 |
KR102207859B1 (ko) | 2021-01-27 |
EP2968545A4 (en) | 2017-01-18 |
KR20150132436A (ko) | 2015-11-25 |
WO2014144763A3 (en) | 2014-12-31 |
US20160032009A1 (en) | 2016-02-04 |
CN105705165A (zh) | 2016-06-22 |
RU2680267C2 (ru) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014144763A3 (en) | High affinity anti-gd2 antibodies | |
PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
MX2017015962A (es) | Uso de exosomas para el tratamiento de enfermedades. | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
BR112018014028A2 (pt) | anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico | |
BR112017010762A2 (pt) | anticorpos anti-pd-1 e métodos de uso dos mesmos | |
BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201992546A1 (ru) | Средства на основе антител к cd33 | |
EA201691877A1 (ru) | Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
CL2016000215A1 (es) | Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14). | |
BR112016030447A2 (pt) | diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno | |
BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
BR112017002342A2 (pt) | novos anticorpos e usos dos mesmos | |
MA40913A (fr) | Conjugués anticorps-médicament | |
BR112015022934A2 (pt) | esteroides neuroativos, composições, e uso do mesmo | |
UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS |